Related Experiment Video
Updated: Feb 21, 2026
06:40
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
1.8K
Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool
Sanjay Kalra1, A G Unnikrishnan2, Manash Baruah3
1Director, Bharti Hospital and BRIDE, Karnal, Haryana, India.
Indian Journal of Endocrinology and Metabolism
|October 10, 2017
Summary
Pharmaco-ergonomics tailors drug therapy to individual needs. A new clinical score tool helps optimize sodium-glucose cotransporter 2 inhibitor (SGLT2-i) use in type-2 diabetes management by balancing risks and benefits.
Area of Science:
- Pharmacology
- Endocrinology
- Clinical Medicine
Background:
- Pharmaco-ergonomics focuses on personalized drug therapy.
- Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) present unique management considerations in type-2 diabetes.
- Optimizing SGLT2-i therapy requires careful evaluation of individual patient factors.
Purpose of the Study:
- To summarize pharmaco-ergonomic considerations for SGLT2-i agents.
- To introduce a novel SGLT2-i qualification tool based on a clinical score.
- To provide a practical guide for optimizing SGLT2-i risk-benefit profiles.
Main Methods:
- Development of a clinical scoring system for SGLT2-i qualification.
- Review of pharmaco-ergonomic principles applied to SGLT2-i therapy.
- Summarization of clinical considerations for SGLT2-i agents.
Main Results:
- A practical SGLT2-i qualification tool has been developed.
- The tool is based on a clinical score to guide therapy selection.
- It aims to simplify risk-benefit assessments for SGLT2-i agents.
Conclusions:
- The proposed SGLT2-i qualification tool offers a simple and inexpensive approach.
- It aids clinicians in optimizing the use of SGLT2-i agents.
- This tool supports informed decision-making in type-2 diabetes management.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
204
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
204
01:55Secondary Active Transport
138.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
138.7K
01:32Secondary Active Transport
9.9K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.9K
01:23Dosage Regimen Designs: Nomograms and Tabulations
234
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
234
01:24Dosage Regimen: Individualization
221
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
221